Internal ADS transfers at Silence Therapeutics (SLN) leave holdings unchanged

Rhea-AI Filing Summary

Silence Therapeutics plc’s 10% owner reported internal ADS transfers with no net change in economic exposure. On August 3, 2025, Ora Capital Limited sold 20,000 American Depositary Shares (ADS) at $5.45 per ADS while Richard Ian Griffiths purchased the same amount. On October 27, 2025, OCL sold a further 2,000 ADS at $7.75 per ADS, again matched by Griffiths buying 2,000 ADS. The filing states these are essentially internal transfers with no change in total beneficial holding, and that each ADS is convertible into three ordinary shares for no consideration.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Griffiths Richard Ian

(Last) (First) (Middle)

19-21 BROAD STREET

(Street)

ST HELIER Y9 JE2 3RR

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Silence Therapeutics plc [ SLN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	$5.45	08/03/2025		S		20,000		(1)	(1)	Ordinary Shares	60,000	(1)	11,805,861	I	See footnote(2)
American Depositary Shares	$5.45	08/03/2025		P		20,000		(1)	(1)	Ordinary Shares	60,000	(1)	11,825,861	I	See footnote(2)
American Depositary Shares	$7.75	10/27/2025		S		2,000		(1)	(1)	Ordinary Shares	6,000	(1)	11,819,861	I	See footnote(2)
American Depositary Shares	$7.75	10/27/2025		P		2,000		(1)	(1)	Ordinary Shares	6,000	(1)	11,825,861	I	See footnote(2)

Explanation of Responses:

1. Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.

2. The securities were sold by Ora Capital Limited ("OCL") and purchased by Mr. Griffiths personally, essentially internal transfers with no change in total beneficial holding. Mr Griffiths is a director and the controlling shareholder of OCL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

	/s/ Richard Ian Griffiths	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Silence Therapeutics (SLN) report in this Form 4?

The Form 4 reports internal transfers of American Depositary Shares. On August 3, 2025, 20,000 ADS traded at $5.45 per ADS, and on October 27, 2025, 2,000 ADS traded at $7.75 per ADS, with matching sales and purchases between related parties.

Who is involved in the Silence Therapeutics (SLN) insider ADS transfers?

The transactions involve Ora Capital Limited and Richard Ian Griffiths, a 10% owner. The securities were sold by Ora Capital Limited and purchased by Mr. Griffiths personally, described as internal transfers with no change in total beneficial holding according to the disclosure.

Did the Silence Therapeutics (SLN) insider ADS transfers change total beneficial ownership?

The filing states there was no change in total beneficial holding. Ora Capital Limited sold ADS that Richard Ian Griffiths bought, so the moves are characterized as internal transfers, effectively reshuffling how the holdings are structured rather than increasing or reducing overall exposure.

At what prices were the Silence Therapeutics (SLN) ADS internal transfers executed?

On August 3, 2025, 20,000 American Depositary Shares changed hands at $5.45 per ADS. On October 27, 2025, 2,000 ADS were transferred at $7.75 per ADS, with equal numbers sold by Ora Capital Limited and purchased by Richard Ian Griffiths.

How many Silence Therapeutics (SLN) ADS were involved and what do they represent?

In total, 22,000 American Depositary Shares were involved across the reported dates. Each ADS is immediately convertible into three ordinary shares for no consideration and has no expiration date, so the ADS represent a larger number of underlying ordinary shares.

What ownership clarification does the Silence Therapeutics (SLN) Form 4 provide about Richard Griffiths?

The disclosure explains that Richard Ian Griffiths is a director and controlling shareholder of Ora Capital Limited. He disclaims beneficial ownership of the securities except to the extent of his proportionate pecuniary interest, clarifying how his economic exposure to the ADS is measured.